Withdrawing Ixekizumab in Patients With Psoriatic Arthritis Who Achieved Minimal Disease Activity: Results From a Randomized, Double‐Blind Withdrawal Study

OBJECTIVE: To evaluate the effect of withdrawing ixekizumab in patients with psoriatic arthritis (PsA) in whom minimal disease activity (MDA) has been achieved after open‐label ixekizumab treatment. METHODS: SPIRIT‐P3 was a multicenter, randomized, double‐blind withdrawal study of biologic treatment...

Descripción completa

Detalles Bibliográficos
Autores principales: Coates, Laura C., Pillai, Sreekumar G., Tahir, Hasan, Valter, Ivo, Chandran, Vinod, Kameda, Hideto, Okada, Masato, Kerr, Lisa, Alves, Denise, Park, So Young, Adams, David H., Gallo, Gaia, Hufford, Matthew M., Hojnik, Maja, Mease, Philip J., Kavanaugh, Arthur
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Psoriatic Arthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8457232/
https://www.ncbi.nlm.nih.gov/pubmed/33682378
http://dx.doi.org/10.1002/art.41716

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8457232/
https://www.ncbi.nlm.nih.gov/pubmed/33682378
http://dx.doi.org/10.1002/art.41716

Ejemplares similares